Hope for rare skin disease: new drug shows promise in trial
NCT ID NCT05856526
First seen Nov 01, 2025
Summary
This study tested a medicine called spesolimab for people with Netherton syndrome, a rare genetic skin condition causing severe redness and scaling. About 43 people aged 12 and older took part, receiving either the drug or a placebo. The goal was to see if spesolimab could reduce skin symptoms over 4 months, with all participants eventually receiving the drug. The trial was stopped early, but results may still offer insights for future treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NETHERTON SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
ASMC-IPSMC-skin and Veneral Diseases
Sofia, 1407, Bulgaria
-
Azienda Ospedaliera Universitaria Citta Della Salute E Della Scienza Di Torino
Torino, 10126, Italy
-
Beijing Children's Hospital, Capital Medical University
Beijing, 100045, China
-
Dermatology Hospital, Chinese Academy of Medical Sciences
Nanjing, 210000, China
-
Erasmus MC Sophia Kinderziekenhuis
Rotterdam, 3015 GD, Netherlands
-
HOP Saint-Louis
Paris, 75010, France
-
Hospital Tunku Azizah
Kuala Lumpur, 50300, Malaysia
-
Istituto Dermopatico Dell'Immacolata - IDI - IRCCS
Roma, 00167, Italy
-
Juntendo University Urayasu Hospital
Chiba, Urayasu, 279-0021, Japan
-
Klinikum der Universität München AÖR
München, 80337, Germany
-
Medical University of South Carolina
Charleston, South Carolina, 29425, United States
-
Mission Dermatology Center
Rancho Santa Margarita, California, 92688, United States
-
Nagoya University Hospital
Aichi, Nagoya, 466-8560, Japan
-
Okayama University Hospital
Okayama, Okayama, 700-8558, Japan
-
Queen Elizabeth University Hospital
Glasgow, G51 4TF, United Kingdom
-
Shanghai Skin Disease Hospital
Shanghai, 200000, China
-
Sourasky Medical Center
Tel Aviv, 6423906, Israel
-
Southern Medical University Dermatology Hospital
Guangzhou, 510091, China
-
The Children's Hospital Zhejiang University School Of Medicine
Hangzhou, 310000, China
-
The First Affiliated Hospital, Zhejiang University
Hangzhou, 310003, China
-
ULS de São José, E.P.E. - Hospital Sto. António Capuchos
Lisbon, 1169-050, Portugal
-
University Children Hospital Zürich
Zurich, 8032, Switzerland
-
Universitätsklinikum Heidelberg
Heidelberg, 69120, Germany
-
Universitätsklinikum Schleswig-Holstein, Campus Kiel
Kiel, 24105, Germany
-
Virginia Clinical Research, Inc.
Norfolk, Virginia, 23502, United States
-
Westmead Hospital
Westmead, New South Wales, 2145, Australia
-
Xinhua Hospital Affiliated to Shanghai Jiaotong University
Shanghai, 200092, China
-
Yale University School of Medicine
New Haven, Connecticut, 06519, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.